519 related articles for article (PubMed ID: 32875077)
1. Targeted Degradation of Oncogenic KRAS
Bond MJ; Chu L; Nalawansha DA; Li K; Crews CM
ACS Cent Sci; 2020 Aug; 6(8):1367-1375. PubMed ID: 32875077
[TBL] [Abstract][Full Text] [Related]
2. Efficient targeted oncogenic KRAS
Yang F; Wen Y; Wang C; Zhou Y; Zhou Y; Zhang ZM; Liu T; Lu X
Eur J Med Chem; 2022 Feb; 230():114088. PubMed ID: 35007863
[TBL] [Abstract][Full Text] [Related]
3. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
[TBL] [Abstract][Full Text] [Related]
4. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective KRAS
Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S
Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of KRAS
Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
[TBL] [Abstract][Full Text] [Related]
7. A Breakthrough Brought about by Targeting KRAS
Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
[TBL] [Abstract][Full Text] [Related]
8. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
9. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
10. Covalent inhibitor targets KRas
Li HY; Qi WL; Wang YX; Meng LH
Genes Dis; 2023 Mar; 10(2):403-414. PubMed ID: 37223497
[No Abstract] [Full Text] [Related]
11. Inhibitors of the GTPase KRAS
Xu Q; Zhang G; Liu Q; Li S; Zhang Y
Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Resistance to Drugs Targeting
Jiao D; Yang S
Innovation (Camb); 2020 Aug; 1(2):. PubMed ID: 32939510
[TBL] [Abstract][Full Text] [Related]
13. Discovery of
Shin Y; Jeong JW; Wurz RP; Achanta P; Arvedson T; Bartberger MD; Campuzano IDG; Fucini R; Hansen SK; Ingersoll J; Iwig JS; Lipford JR; Ma V; Kopecky DJ; McCarter J; San Miguel T; Mohr C; Sabet S; Saiki AY; Sawayama A; Sethofer S; Tegley CM; Volak LP; Yang K; Lanman BA; Erlanson DA; Cee VJ
ACS Med Chem Lett; 2019 Sep; 10(9):1302-1308. PubMed ID: 31531201
[TBL] [Abstract][Full Text] [Related]
14. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
[TBL] [Abstract][Full Text] [Related]
15. Progress on Covalent Inhibition of KRAS(G12C).
Westover KD; Jänne PA; Gray NS
Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
[TBL] [Abstract][Full Text] [Related]
16. Development of a biotin-streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRAS
Liu S; Shi J; Li H; Li J; Zhu Y; Li B; Sun Y
SLAS Discov; 2022 Mar; 27(2):107-113. PubMed ID: 35058184
[TBL] [Abstract][Full Text] [Related]
17. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
18. Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC.
Swartzel JC; Bond MJ; Pintado-Urbanc AP; Daftary M; Krone MW; Douglas T; Carder EJ; Zimmer JT; Maeda T; Simon MD; Crews CM
ACS Chem Biol; 2022 Jul; 17(7):1789-1798. PubMed ID: 35749470
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
